20160501 CCMG-CCGM - Poster Presentations - Part 2

Interactive session with the authors of poster presentations.

MG-114 WDR26 haploinsufficiency causes a recognizable syndrome of intellectual disability, seizures, abnormal gait, and distinctive facial features
Dr. Matt Deardorff, Children's Hospital of Philadelphia

MG-115 Algorithmic analysis of all possible mitochondrial tRNA mutations
Dr. Neal Sondheimer, The Hospital for Sick Children

MG-116 Identification of a DNA methylation signature of PTEN loss in prostate cancer
Dr. Erfan Aref-Eshghi, University of Western Ontario

MG-117 Proposed guidelines for utilization of the comprehensive assessment of sequence and copy number mutations in Epilepsy-related disorders in Ontario
Dr. Bekim Sadikovic

MG-118 Mutations in cellular mechanotransduction genes are associated with idiopathic scoliosis. A genetics and cellular based evidence study
Ms Niaz Oliazadeh, CHU Saint-Justine

MG-119 Discrepant genotype-phenotype correlation in two siblings with hypophosphatasia
Dr. Alan O'Brien, Hospital for Sick Children

MG-120 Explaining the 'missing heritability' in schizophrenia: preliminary evidence using a large number of exomes
Ms Vanessa Fulginiti, McGill University

MG-121 Chromosome 2q duplication: A case report on a recombinant chromosome 2 with pure 2q24.3q36.1 duplication.
Dr. Tchakarska Gany

MG-122 Cohen Syndrome: a mitochondrial masquerader?
Dr. Karen Niederhoffer, University of Alberta

MG-124 A report of a novel variant in a case with familial dilated cardiomyopathy (DCM)
Ms Sahar Mikaeeli

MG-125 Panel based study for genetic diagnosis of arrhythmia
Ms Sahar Mikaeeli

MG-126 Regulation of Matrix Gla Protein Gene Expression by an Intronic Sequence
Mr. Jobran Mohammed Moshi

MG-127 Mutations In MYBPC1 Gene Are Associated With Myogenic Tremor
Dr. Baiba Lace

MG-128 Detection of microdeletion/microduplication using next generation sequencing; three case studies.
Dr. Jeanne Morin-Leisk

Question Title

* 1. Please Rate Each Session:

	Did Not Attend	Poor	Fair	Good	Very Good	Excellent
MG-114 WDR26 haploinsufficiency causes a recognizable syndrome of intellectual disability, seizures, abnormal gait, and distinctive facial features	MG-114 WDR26 haploinsufficiency causes a recognizable syndrome of intellectual disability, seizures, abnormal gait, and distinctive facial features Did Not Attend	MG-114 WDR26 haploinsufficiency causes a recognizable syndrome of intellectual disability, seizures, abnormal gait, and distinctive facial features Poor	MG-114 WDR26 haploinsufficiency causes a recognizable syndrome of intellectual disability, seizures, abnormal gait, and distinctive facial features Fair	MG-114 WDR26 haploinsufficiency causes a recognizable syndrome of intellectual disability, seizures, abnormal gait, and distinctive facial features Good	MG-114 WDR26 haploinsufficiency causes a recognizable syndrome of intellectual disability, seizures, abnormal gait, and distinctive facial features Very Good	MG-114 WDR26 haploinsufficiency causes a recognizable syndrome of intellectual disability, seizures, abnormal gait, and distinctive facial features Excellent
MG-115 Algorithmic analysis of all possible mitochondrial tRNA mutations	MG-115 Algorithmic analysis of all possible mitochondrial tRNA mutations Did Not Attend	MG-115 Algorithmic analysis of all possible mitochondrial tRNA mutations Poor	MG-115 Algorithmic analysis of all possible mitochondrial tRNA mutations Fair	MG-115 Algorithmic analysis of all possible mitochondrial tRNA mutations Good	MG-115 Algorithmic analysis of all possible mitochondrial tRNA mutations Very Good	MG-115 Algorithmic analysis of all possible mitochondrial tRNA mutations Excellent
MG-116 Identification of a DNA methylation signature of PTEN loss in prostate cancer	MG-116 Identification of a DNA methylation signature of PTEN loss in prostate cancer Did Not Attend	MG-116 Identification of a DNA methylation signature of PTEN loss in prostate cancer Poor	MG-116 Identification of a DNA methylation signature of PTEN loss in prostate cancer Fair	MG-116 Identification of a DNA methylation signature of PTEN loss in prostate cancer Good	MG-116 Identification of a DNA methylation signature of PTEN loss in prostate cancer Very Good	MG-116 Identification of a DNA methylation signature of PTEN loss in prostate cancer Excellent
MG-117 Proposed guidelines for utilization of the comprehensive assessment of sequence and copy number mutations in Epilepsy-related disorders in Ontario	MG-117 Proposed guidelines for utilization of the comprehensive assessment of sequence and copy number mutations in Epilepsy-related disorders in Ontario Did Not Attend	MG-117 Proposed guidelines for utilization of the comprehensive assessment of sequence and copy number mutations in Epilepsy-related disorders in Ontario Poor	MG-117 Proposed guidelines for utilization of the comprehensive assessment of sequence and copy number mutations in Epilepsy-related disorders in Ontario Fair	MG-117 Proposed guidelines for utilization of the comprehensive assessment of sequence and copy number mutations in Epilepsy-related disorders in Ontario Good	MG-117 Proposed guidelines for utilization of the comprehensive assessment of sequence and copy number mutations in Epilepsy-related disorders in Ontario Very Good	MG-117 Proposed guidelines for utilization of the comprehensive assessment of sequence and copy number mutations in Epilepsy-related disorders in Ontario Excellent
MG-118 Mutations in cellular mechanotransduction genes are associated with idiopathic scoliosis. A genetics and cellular based evidence study	MG-118 Mutations in cellular mechanotransduction genes are associated with idiopathic scoliosis. A genetics and cellular based evidence study Did Not Attend	MG-118 Mutations in cellular mechanotransduction genes are associated with idiopathic scoliosis. A genetics and cellular based evidence study Poor	MG-118 Mutations in cellular mechanotransduction genes are associated with idiopathic scoliosis. A genetics and cellular based evidence study Fair	MG-118 Mutations in cellular mechanotransduction genes are associated with idiopathic scoliosis. A genetics and cellular based evidence study Good	MG-118 Mutations in cellular mechanotransduction genes are associated with idiopathic scoliosis. A genetics and cellular based evidence study Very Good	MG-118 Mutations in cellular mechanotransduction genes are associated with idiopathic scoliosis. A genetics and cellular based evidence study Excellent
MG-119 Discrepant genotype-phenotype correlation in two siblings with hypophosphatasia	MG-119 Discrepant genotype-phenotype correlation in two siblings with hypophosphatasia Did Not Attend	MG-119 Discrepant genotype-phenotype correlation in two siblings with hypophosphatasia Poor	MG-119 Discrepant genotype-phenotype correlation in two siblings with hypophosphatasia Fair	MG-119 Discrepant genotype-phenotype correlation in two siblings with hypophosphatasia Good	MG-119 Discrepant genotype-phenotype correlation in two siblings with hypophosphatasia Very Good	MG-119 Discrepant genotype-phenotype correlation in two siblings with hypophosphatasia Excellent
MG-120 Explaining the 'missing heritability' in schizophrenia: preliminary evidence using a large number of exomes	MG-120 Explaining the 'missing heritability' in schizophrenia: preliminary evidence using a large number of exomes Did Not Attend	MG-120 Explaining the 'missing heritability' in schizophrenia: preliminary evidence using a large number of exomes Poor	MG-120 Explaining the 'missing heritability' in schizophrenia: preliminary evidence using a large number of exomes Fair	MG-120 Explaining the 'missing heritability' in schizophrenia: preliminary evidence using a large number of exomes Good	MG-120 Explaining the 'missing heritability' in schizophrenia: preliminary evidence using a large number of exomes Very Good	MG-120 Explaining the 'missing heritability' in schizophrenia: preliminary evidence using a large number of exomes Excellent
MG-121 Chromosome 2q duplication: A case report on a recombinant chromosome 2 with pure 2q24.3q36.1 duplication.	MG-121 Chromosome 2q duplication: A case report on a recombinant chromosome 2 with pure 2q24.3q36.1 duplication. Did Not Attend	MG-121 Chromosome 2q duplication: A case report on a recombinant chromosome 2 with pure 2q24.3q36.1 duplication. Poor	MG-121 Chromosome 2q duplication: A case report on a recombinant chromosome 2 with pure 2q24.3q36.1 duplication. Fair	MG-121 Chromosome 2q duplication: A case report on a recombinant chromosome 2 with pure 2q24.3q36.1 duplication. Good	MG-121 Chromosome 2q duplication: A case report on a recombinant chromosome 2 with pure 2q24.3q36.1 duplication. Very Good	MG-121 Chromosome 2q duplication: A case report on a recombinant chromosome 2 with pure 2q24.3q36.1 duplication. Excellent
MG-122 Cohen Syndrome: a mitochondrial masquerader?	MG-122 Cohen Syndrome: a mitochondrial masquerader? Did Not Attend	MG-122 Cohen Syndrome: a mitochondrial masquerader? Poor	MG-122 Cohen Syndrome: a mitochondrial masquerader? Fair	MG-122 Cohen Syndrome: a mitochondrial masquerader? Good	MG-122 Cohen Syndrome: a mitochondrial masquerader? Very Good	MG-122 Cohen Syndrome: a mitochondrial masquerader? Excellent
MG-124 A report of a novel variant in a case with familial dilated cardiomyopathy (DCM)	MG-124 A report of a novel variant in a case with familial dilated cardiomyopathy (DCM) Did Not Attend	MG-124 A report of a novel variant in a case with familial dilated cardiomyopathy (DCM) Poor	MG-124 A report of a novel variant in a case with familial dilated cardiomyopathy (DCM) Fair	MG-124 A report of a novel variant in a case with familial dilated cardiomyopathy (DCM) Good	MG-124 A report of a novel variant in a case with familial dilated cardiomyopathy (DCM) Very Good	MG-124 A report of a novel variant in a case with familial dilated cardiomyopathy (DCM) Excellent
MG-125 Panel based study for genetic diagnosis of arrhythmia	MG-125 Panel based study for genetic diagnosis of arrhythmia Did Not Attend	MG-125 Panel based study for genetic diagnosis of arrhythmia Poor	MG-125 Panel based study for genetic diagnosis of arrhythmia Fair	MG-125 Panel based study for genetic diagnosis of arrhythmia Good	MG-125 Panel based study for genetic diagnosis of arrhythmia Very Good	MG-125 Panel based study for genetic diagnosis of arrhythmia Excellent
MG-126 Regulation of Matrix Gla Protein Gene Expression by an Intronic Sequence	MG-126 Regulation of Matrix Gla Protein Gene Expression by an Intronic Sequence Did Not Attend	MG-126 Regulation of Matrix Gla Protein Gene Expression by an Intronic Sequence Poor	MG-126 Regulation of Matrix Gla Protein Gene Expression by an Intronic Sequence Fair	MG-126 Regulation of Matrix Gla Protein Gene Expression by an Intronic Sequence Good	MG-126 Regulation of Matrix Gla Protein Gene Expression by an Intronic Sequence Very Good	MG-126 Regulation of Matrix Gla Protein Gene Expression by an Intronic Sequence Excellent
Mutations In MYBPC1 Gene Are Associated With Myogenic Tremor	Mutations In MYBPC1 Gene Are Associated With Myogenic Tremor Did Not Attend	Mutations In MYBPC1 Gene Are Associated With Myogenic Tremor Poor	Mutations In MYBPC1 Gene Are Associated With Myogenic Tremor Fair	Mutations In MYBPC1 Gene Are Associated With Myogenic Tremor Good	Mutations In MYBPC1 Gene Are Associated With Myogenic Tremor Very Good	Mutations In MYBPC1 Gene Are Associated With Myogenic Tremor Excellent
MG-128 Detection of microdeletion/microduplication using next generation sequencing; three case studies.	MG-128 Detection of microdeletion/microduplication using next generation sequencing; three case studies. Did Not Attend	MG-128 Detection of microdeletion/microduplication using next generation sequencing; three case studies. Poor	MG-128 Detection of microdeletion/microduplication using next generation sequencing; three case studies. Fair	MG-128 Detection of microdeletion/microduplication using next generation sequencing; three case studies. Good	MG-128 Detection of microdeletion/microduplication using next generation sequencing; three case studies. Very Good	MG-128 Detection of microdeletion/microduplication using next generation sequencing; three case studies. Excellent

Question Title

* 2. Please assess the Sessions as a whole

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Sufficient time was allowed for audience participation/active learning	Sufficient time was allowed for audience participation/active learning Strongly Disagree	Sufficient time was allowed for audience participation/active learning Disagree	Sufficient time was allowed for audience participation/active learning Neutral	Sufficient time was allowed for audience participation/active learning Agree	Sufficient time was allowed for audience participation/active learning Strongly Agree
The facilities were satisfactory	The facilities were satisfactory Strongly Disagree	The facilities were satisfactory Disagree	The facilities were satisfactory Neutral	The facilities were satisfactory Agree	The facilities were satisfactory Strongly Agree
The session was free from commercial bias	The session was free from commercial bias Strongly Disagree	The session was free from commercial bias Disagree	The session was free from commercial bias Neutral	The session was free from commercial bias Agree	The session was free from commercial bias Strongly Agree
Overall, I would rate this Symposium as excellent	Overall, I would rate this Symposium as excellent Strongly Disagree	Overall, I would rate this Symposium as excellent Disagree	Overall, I would rate this Symposium as excellent Neutral	Overall, I would rate this Symposium as excellent Agree	Overall, I would rate this Symposium as excellent Strongly Agree

Question Title

* 3. As a result of attending these sessions, I am planning to:

a) Discuss the session with my colleagues

b) Pursue additional learning activities.

c) Complete a Personal Learning Project.

d) Not change my practice.

e) Change my practice.

Question Title

* 4. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Medical Expert

Communicator

Collaborator

Manager

Health Advocate

Scholar

Professional

20160501 CCMG-CCGM - Poster Presentations - Part 2

Interactive session with the authors of poster presentations.

Question Title

* 1. Please Rate Each Session:

Question Title

* 2. Please assess the Sessions as a whole

Question Title

* 3. As a result of attending these sessions, I am planning to:

Question Title

* 4. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 6. General comments about individual speakers:

Question Title

* 7. What topics would you like to be addressed at future conferences to keep you up to date in your profession?